Holen Sie sich die Stockscreener-App
153.83
0.67%
-1.04
Handel nachbörslich:
150.00
-3.83
-2.49%
Schlusskurs vom Vortag:
$154.87
Offen:
$154.88
24-Stunden-Volumen:
1.01M
Relative Volume:
0.84
Marktkapitalisierung:
$10.65B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
35.80
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
-0.50%
1M Leistung:
-18.85%
6M Leistung:
-52.93%
1J Leistung:
-52.13%
1-Tages-Spanne:
$152.97
$156.50
1-Wochen-Bereich:
$150.07
$158.15
52-Wochen-Spanne:
$145.59
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
153.80 | 10.73B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
86.66 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.95 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.59 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.66 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.56 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
Beta Bionics to launch its first insulin patch pump to compete with Insulet - Yahoo Finance
11 Best Medical Technology Stocks to Buy Right Now - Insider Monkey
Are Wall Street Analysts Bullish on Insulet Stock? - Barchart.com
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Here’s Insiders Fund’s Thesis on Insulet Corporation (PODD) - Insider Monkey
PODD News | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corporation (PODD) Announces Amendments to Bylaws and An - GuruFocus
Insulet Corp (PODD) director granted 1,660 RSUs vesting in 2027 - Stock Titan
Insulet (PODD) director receives 1,660 RSU equity award vesting in 2027 - Stock Titan
Insulet (PODD) director Timothy Scannell receives 1,660-share RSU equity award - Stock Titan
Insulet (PODD) director Minogue receives 1,660 RSUs and reports trust-held shares - Stock Titan
Insulet (PODD) director awarded 1,660 RSUs in deferred stock grant - Stock Titan
Director at Insulet (NASDAQ: PODD) receives 1,660-share RSU grant - Stock Titan
Insulet (PODD) director granted 1,660 RSUs, total holdings now 3,818 shares - Stock Titan
Insulet (PODD) director Luciana Borio receives 1,660-share RSU equity grant - Stock Titan
Insulet (NASDAQ: PODD) amends bylaws and confirms 2026 shareholder voting outcomes - Stock Titan
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corp stock (US45784P1012): William Blair starts coverage as after-hours drop tests investor - AD HOC NEWS
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Assumed by William Blair -- Rating Action: Outperform - GuruFocus
William Blair initiates Insulet stock coverage with Outperform rating - Investing.com
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
A Look At Insulet (PODD) Valuation After A Sharp Share Price Pullback - Yahoo Finance
Insulet Corp stock (US45784P1012): after Q1 beat and raised outlook, investors eye diabetes tech gro - AD HOC NEWS
Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tel - GuruFocus
Insulet Corporation $PODD Stock Holdings Increased by DNB Asset Management AS - MarketBeat
Insulet Corp stock (US45784P1012): diabetes tech player after earnings beat and sharp pullback - AD HOC NEWS
The 5 Most Interesting Analyst Questions From Insulet’s Q1 Earnings Call - Yahoo Finance
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet (PODD) CEO McEvoy uses 1,411 shares to cover RSU taxes - Stock Titan
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) - The Globe and Mail
This Insulet analyst is no longer bullish; here are top 4 downgrades for Friday - MSN
Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results - Insider Monkey
Insulet Corp stock (US45784P1012): Hits 52-week low at $148.24 - AD HOC NEWS
Capital Research holds 2.4% of Insulet (NASDAQ: PODD) in Schedule 13G/A - Stock Titan
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
A Look at Insulet Corp (PODD) After 6.0% Decline -- GF Value $38 - GuruFocus
A Look at Insulet Corp (PODD) After 6.0% Decline -- GF Value $385.97 vs Price $148.84 - GuruFocus
Insulet Corporation Stock Watch Rises With Nasdaq Composite Activity - Kalkine Media
Insulet Corporation stock hits 52-week low at 148.24 USD - Investing.com
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - Yahoo Finance
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Insulet (NASDAQ:PODD) Shares Unloaded Sen. Tina Smith - MarketBeat
Sen. Tina Smith Sells Insulet Corporation (NASDAQ:PODD) Stock - MarketBeat
Benchmark reaffirms Insulet stock rating with $250 price target - Investing.com
Benchmark reaffirms Insulet stock rating with $250 price target By Investing.com - Investing.com UK
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh - TradingView
Why Insulet (PODD) is a Top Value Stock for the Long-Term - Yahoo Finance
Insulet Corp. Stock Hits Day Low Amid Price Pressure, Drops to $148.45 - Markets Mojo
Mitsubishi UFJ Asset Management Co. Ltd. Purchases 8,172 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corp (PODD) Shares Fall 3.8% -- What GF Score of 83 Tells Investors - GuruFocus
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):